Exploring the Science and Appreciating the Patient Experience: Early, Individualized Therapy to Optimize Outcomes in Multiple Sclerosis

 

 

PROGRAM OVERVIEW

Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This expert-faculty video discussion activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this interactive case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared-decision making (SDM).

 

FACULTY

Aaron L. Boster, MD
Owner & Physician
The Boster Center for Multiple Sclerosis
Columbus, Ohio

 

Claire Riley, MD
Assistant Professor of Neurology
Medical Director, Columbia MS Center
Columbia University Irving Medical Center
New York, New York

 

Release date: September 11, 2019
Expiration date: September 11, 2020
Estimated time to complete activity: 1.0 hour

 

TARGET AUDIENCE

This program is intended for MS specialists, neurologists, internists, and allied healthcare professionals involved in the care and management of patients with MS.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe current perspectives regarding early, efficacious treatment of active MS disease to prevent irreversible neurologic damage
  • Compare the mechanisms of action and efficacy of currently available and emerging MS treatments in order to better individualize patient treatment plans
  • Design therapeutic strategies encompassing patient efficacy outcomes, safety and tolerability considerations, reimbursement strategies and consideration, as well as patient preferences, when selecting a DMT
  • Implement a multidisciplinary treatment strategy involving SDM along with appropriate patient resources to improve the management of patients with MS
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 11, 2019 through September 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme
Contracted Research: Biogen MA, Inc., Genentech, Johnson & Johnson

Claire Riley, MD
Consulting Fees: Biogen MA, Inc., EMD Serono, TG Therapeutics

The Integrity Continuing Education, Inc. planners and their spouses/life partners have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by individual educational grants from Biogen MA, Inc. and Novartis Pharmaceuticals Corporation. This activity was supported by an educational grant from Celgene Corporation.

Continue to Pretest